VIP236
Metastatic Solid Tumors
Phase 1Active
Key Facts
About Vincerx Pharma
Vincerx Pharma is a NASDAQ-listed biotech (VINC) with a mission to address high unmet needs in oncology by developing novel therapeutics. The company employs a capital-efficient, virtual R&D model to in-license and advance a pipeline of targeted and immuno-oncology candidates. Its strategy centers on precise asset selection, biomarker-driven development, and exploring combination regimens to overcome therapeutic resistance. Despite facing significant financial and operational challenges common to early-stage biotechs, Vincerx aims to create value through disciplined pipeline progression and strategic partnerships.
View full company profileTherapeutic Areas
Other Metastatic Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| ECM-Targeted Radiopharmaceutical | Matrisome Bio | Pre-clinical |
| MSC-1 (anti-LIF mAb) | Sorrento Therapeutics | Phase 1 |
| TTX-MC138 | TransCode Therapeutics | Phase I |